Vestibular Schwannoma Growth Rates in Neurofibromatosis Type 2 Natural History Consortium Subjects

Slattery, William H.; Fisher, Laurel M.; Iqbal, Zarina; Oppenhiemer, Mark

doi:10.1097/00129492-200409000-00027

Cited by 71 publications

(44 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reasons for drug interruptions included surgery for a non-vestibular tumor (6), adverse event (6, including 1 hypertension, 2 proteinuria, 2 menorrhagia, and 1 pneumonia), loss of insurance coverage (3), and patient preference (2 …”

Section: Drug Interruptionsmentioning

confidence: 99%

Bevacizumab for Progressive Vestibular Schwannoma in Neurofibromatosis Type 2

Plotkin¹,

Merker²,

Halpin³

et al. 2012

Otology &Amp; Neurotology

219

150

View full text Add to dashboard Cite

Objective: Early studies suggest that bevacizumab treatment can result in tumor shrinkage and hearing improvement for some patients with neurofibromatosis 2 (NF2). The aim of this study was to report extended follow-up in a larger cohort of similarly treated patients.Study Design: Retrospective study. Setting: Tertiary referral centerPatients: 31 consecutive NF2 patients who received bevacizumab for progressive vestibular schwannomas.Main Outcome Measure: Hearing improvement, defined as an improvement in word recognition score above the 95% critical difference compared with baseline, and radiographic response, defined as a ≥20% decrease in tumor volume compared with baseline. Results:The median age was 26 years (range, 12-73). The median volumetric tumor growth rate before treatment was 64% per year. At the time of analysis, the median duration of treatment was 14 months (range, 6-41) with a total of 45 patient-years of follow up. A hearing response occurred in 13/23 (57%) evaluable patients, and a radiographic response in 17/31 (55%) of target vestibular schwannomas. The median time to response was 3 months for both endpoints. The only clinical or radiographic feature at baseline that correlated with change in tumor volume at 3 months was the mean apparent diffusion coefficient (ADC) value, a radiologic marker of edema (p=0.036). 90% of patients had stable or improved hearing after 1 year of treatment and 61% at 3 years. 88% of patients had stable or decreased tumor size after 1 year of treatment and 54% at 3 years. Overall, treatment was well tolerated.Conclusion: Bevacizumab treatment was followed by hearing improvement and tumor shrinkage in over 50% of progressive vestibular schwannomas in NF2 patients. Stable or 2 improved hearing was retained in the majority of patients.3

show abstract

Section: Drug Interruptionsmentioning

confidence: 99%

Bevacizumab for Progressive Vestibular Schwannoma in Neurofibromatosis Type 2

Plotkin¹,

Merker²,

Halpin³

et al. 2012

Otology &Amp; Neurotology

219

150

View full text Add to dashboard Cite

show abstract

“…Study participants were aged 5 years or older and had at least 1 untreated VS 17 . A total of 141 patients were recruited for the study by the NF2 Natural History Consortium at 10 international medical centers with expertise in NF2 (see text, Supplemental Digital Content 1 for full list of centers and principal investigators).…”

Section: Study Cohortmentioning

confidence: 99%

“…Patients were followed using serial MRI and audiometry studies, and results were reported in previous publications. [14][15][16][17][18] In the present study, we used the data acquired by the NF2 Natural History Consortium in an analysis intended specifically to inform design of future trials of therapy in NF2-related VS. Specifically, we aimed to define the expected rates over time of tumor growth and hearing decline using endpoints shown to be feasible in recent clinical trials for NF2-related VS.…”

Section: Introductionmentioning

confidence: 99%

Natural History of Vestibular Schwannoma Growth and Hearing Decline in Newly Diagnosed Neurofibromatosis Type 2 Patients

Plotkin¹,

Merker²,

Muzikansky³

et al. 2014

Otology &Amp; Neurotology

View full text Add to dashboard Cite

“…Patients with the diagnosis of neurofibromatosis type 2 (NF-2) were excluded from the study because their tumor-growth characteristics are different from those of sporadic VS. [15][16][17] Eighteen patients were identified.…”

Section: Patientsmentioning

confidence: 99%

Diagnostic Accuracy of the Constructive Interference in Steady State Sequence Alone for Follow-Up Imaging of Vestibular Schwannomas

Özgen¹,

Oğuz²,

Dolgun³

2009

AJNR Am J Neuroradiol

View full text Add to dashboard Cite

BACKGROUND AND PURPOSE: Vestibular schwannoma (VS) is a benign, slow-growing tumor, and radiologic monitoring is an acceptable alternative to surgery in small lesions and in elderly patients. MR imaging with contrast is the study of choice in the follow-up of these lesions. However, gadoliniumbased contrast agents have side effects and should be used only when definitely indicated. The purpose of this study was to evaluate the diagnostic accuracy of the constructive interference in steady state (CISS) sequence used without postcontrast sequences for the follow-up imaging of VS.

show abstract

Vestibular Schwannoma Growth Rates in Neurofibromatosis Type 2 Natural History Consortium Subjects

Abstract: Slightly greater than 1 in 10 diagnosed NF2-related vestibular schwannomas increased in size by at least 5 mm by 4 years of follow-up, if still untreated at that time.

Cited by 71 publications

References 22 publications

Bevacizumab for Progressive Vestibular Schwannoma in Neurofibromatosis Type 2

Bevacizumab for Progressive Vestibular Schwannoma in Neurofibromatosis Type 2

Natural History of Vestibular Schwannoma Growth and Hearing Decline in Newly Diagnosed Neurofibromatosis Type 2 Patients

Diagnostic Accuracy of the Constructive Interference in Steady State Sequence Alone for Follow-Up Imaging of Vestibular Schwannomas

Contact Info

Product

Resources

About